Article

ARID1A-mutant and deficient bladder cancer is sensitive to EZH2 pharmacologic inhibition

2021-01-13

Abstract excerpt

Metastatic urothelial carcinoma of the bladder is generally incurable by current systemic therapy. Molecular characterization of bladder cancer (BLCa) has revealed multiple candidate driver genes for BLCa tumorigenesis. Epigenetic/chromatin modifiers have been shown to be frequently mutated in BLCa, with ARID1A mutations highly prevalent in nearly 20% of early and late stage tumors. EZH2 is a histone methyltransfe...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: b0097efb-d56d-5975-8810-ac5fef5a3c65
DOI: 10.1101/2021.01.12.426383

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

ARID1A-mutant and deficient bladder cancer is sensitive to EZH2 pharmacologic inhibitionDOI 10.1101/2021.01.12.426383Read

ARID1A-deficient bladder cancer is dependent on PI3K signaling and sensitive to EZH2 and PI3K inhibitorsSemantic proximity Read

Therapeutic significance of ARID1A mutation in bladder cancer.Semantic proximity Read

ARID1A-deficiency in urothelial bladder cancer: No predictive biomarker for EZH2-inhibitor treatment response?Semantic proximity Read

Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of ARID1A Mutant Cancers.Semantic proximity Read

EZH2 in Bladder Cancer, a Promising Therapeutic TargetSemantic proximity Read

ARID1A Alterations Are Associated with FGFR3-Wild Type, Poor-Prognosis, Urothelial Bladder TumorsSemantic proximity Read

EZH2 inhibition in ARID1A mutated clear cell and endometrioid ovarian and endometrioid endometrial cancersSemantic proximity Read

Integrative analysis of patient-derived tumoroids and ex vivo organoid modelling of ARID1A loss in bladder cancer reveals therapeutic molecular targetsSemantic proximity Read

<i>In Vivo</i> Disruption of an Rb–E2F–Ezh2 Signaling Loop Causes Bladder CancerSemantic proximity Read

Integrative analysis of patient-derived tumoroids and ex vivo organoid modeling of ARID1A loss in bladder cancer reveals therapeutic molecular targetsSemantic proximity Read

Activation of EZH2 and SUZ12 Regulated by E2F1 Predicts the Disease Progression and Aggressive Characteristics of Bladder CancerSemantic proximity Read

BMAL2 is a druggable target for ARID1A-wildtype ovarian clear cell carcinoma (OCCC)Semantic proximity Read